Spyglass Pharma (SGP) Competitors

$21.20 -1.04 (-4.68%)

Closing price 04:00 PM Eastern

Extended Trading

$21.20 +0.00 (+0.02%)

As of 04:10 PM Eastern

SGP vs. WRBY, SLNO, LMAT, TMDX, and AXGN

Should you buy Spyglass Pharma stock or one of its competitors? MarketBeat compares Spyglass Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spyglass Pharma include Warby Parker (WRBY), Soleno Therapeutics (SLNO), LeMaitre Vascular (LMAT), TransMedics Group (TMDX), and AxoGen (AXGN). These companies are all part of the "medical equipment" industry.

How does Spyglass Pharma compare to Warby Parker?

Spyglass Pharma (NASDAQ:SGP) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Warby Parker has a net margin of 0.15% compared to Spyglass Pharma's net margin of 0.00%. Warby Parker's return on equity of 2.30% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Warby Parker	0.15%	2.30%	1.18%

In the previous week, Warby Parker had 13 more articles in the media than Spyglass Pharma. MarketBeat recorded 16 mentions for Warby Parker and 3 mentions for Spyglass Pharma. Warby Parker's average media sentiment score of 0.45 beat Spyglass Pharma's score of -0.28 indicating that Warby Parker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Warby Parker	6 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Warby Parker has higher revenue and earnings than Spyglass Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
Warby Parker	$871.91M	3.12	$1.64M	$0.02	1,268.70

93.2% of Warby Parker shares are held by institutional investors. 16.8% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spyglass Pharma presently has a consensus target price of $45.00, suggesting a potential upside of 112.26%. Warby Parker has a consensus target price of $29.00, suggesting a potential upside of 14.29%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Spyglass Pharma is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Warby Parker	0 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Warby Parker beats Spyglass Pharma on 9 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to Soleno Therapeutics?

Soleno Therapeutics (NASDAQ:SLNO) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Soleno Therapeutics presently has a consensus price target of $76.67, suggesting a potential upside of 44.63%. Spyglass Pharma has a consensus price target of $45.00, suggesting a potential upside of 112.26%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Soleno Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Soleno Therapeutics has a net margin of 33.70% compared to Spyglass Pharma's net margin of 0.00%. Soleno Therapeutics' return on equity of 22.85% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Spyglass Pharma	N/A	N/A	N/A

In the previous week, Soleno Therapeutics and Soleno Therapeutics both had 3 articles in the media. Spyglass Pharma's average media sentiment score of -0.28 beat Soleno Therapeutics' score of -1.00 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soleno Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.4% of Soleno Therapeutics shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Soleno Therapeutics has higher revenue and earnings than Spyglass Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$190.40M	14.51	$20.89M	$1.77	29.95
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

Summary

Soleno Therapeutics beats Spyglass Pharma on 6 of the 10 factors compared between the two stocks.

How does Spyglass Pharma compare to LeMaitre Vascular?

Spyglass Pharma (NASDAQ:SGP) and LeMaitre Vascular (NASDAQ:LMAT) are both medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

84.6% of LeMaitre Vascular shares are owned by institutional investors. 7.4% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, LeMaitre Vascular had 2 more articles in the media than Spyglass Pharma. MarketBeat recorded 5 mentions for LeMaitre Vascular and 3 mentions for Spyglass Pharma. LeMaitre Vascular's average media sentiment score of 0.79 beat Spyglass Pharma's score of -0.28 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
LeMaitre Vascular	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

LeMaitre Vascular has a net margin of 24.35% compared to Spyglass Pharma's net margin of 0.00%. LeMaitre Vascular's return on equity of 15.36% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
LeMaitre Vascular	24.35%	15.36%	9.78%

LeMaitre Vascular has higher revenue and earnings than Spyglass Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
LeMaitre Vascular	$256.28M	9.03	$57.73M	$2.71	37.39

Spyglass Pharma currently has a consensus price target of $45.00, indicating a potential upside of 112.26%. LeMaitre Vascular has a consensus price target of $112.60, indicating a potential upside of 11.12%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Spyglass Pharma is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

LeMaitre Vascular beats Spyglass Pharma on 9 of the 12 factors compared between the two stocks.

How does Spyglass Pharma compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

TransMedics Group currently has a consensus target price of $135.00, indicating a potential upside of 104.14%. Spyglass Pharma has a consensus target price of $45.00, indicating a potential upside of 112.26%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

TransMedics Group has higher revenue and earnings than Spyglass Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	3.77	$190.29M	$4.40	15.03
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

In the previous week, TransMedics Group and TransMedics Group both had 3 articles in the media. TransMedics Group's average media sentiment score of -0.11 beat Spyglass Pharma's score of -0.28 indicating that TransMedics Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group has a net margin of 27.04% compared to Spyglass Pharma's net margin of 0.00%. TransMedics Group's return on equity of 22.38% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Spyglass Pharma	N/A	N/A	N/A

99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

TransMedics Group beats Spyglass Pharma on 8 of the 10 factors compared between the two stocks.

How does Spyglass Pharma compare to AxoGen?

Spyglass Pharma (NASDAQ:SGP) and AxoGen (NASDAQ:AXGN) are both medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, AxoGen had 7 more articles in the media than Spyglass Pharma. MarketBeat recorded 10 mentions for AxoGen and 3 mentions for Spyglass Pharma. AxoGen's average media sentiment score of 0.88 beat Spyglass Pharma's score of -0.28 indicating that AxoGen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyglass Pharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AxoGen	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Spyglass Pharma has a net margin of 0.00% compared to AxoGen's net margin of -13.21%. Spyglass Pharma's return on equity of 0.00% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
AxoGen	-13.21%	-9.63%	-6.26%

Spyglass Pharma has higher earnings, but lower revenue than AxoGen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
AxoGen	$225.21M	10.08	-$15.70M	-$0.64	N/A

Spyglass Pharma currently has a consensus price target of $45.00, suggesting a potential upside of 112.26%. AxoGen has a consensus price target of $46.50, suggesting a potential upside of 8.92%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe Spyglass Pharma is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
AxoGen	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

AxoGen beats Spyglass Pharma on 6 of the 11 factors compared between the two stocks.

Get Spyglass Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGP vs. The Competition

Export

Metric	Spyglass Pharma	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$708.65M	$3.26B	$4.14B	$12.10B
Dividend Yield	N/A	N/A	6.12%	5.32%
P/E Ratio	N/A	3.25	22.65	25.11
Price / Sales	N/A	29.58	118.56	91.32
Price / Cash	N/A	4.27	50.53	37.30
Price / Book	N/A	3.81	37.62	6.60
Net Income	N/A	-$76.79M	$113.56M	$335.71M
7 Day Performance	-12.18%	-1.69%	-0.75%	-2.03%
1 Month Performance	-15.00%	-4.64%	-0.67%	-1.90%
1 Year Performance	N/A	89.33%	13.72%	27.36%

Spyglass Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGP Spyglass Pharma	N/A	$21.20 -4.7%	$45.00 +112.3%	N/A	$708.65M	N/A	N/A	65	News Coverage Earnings Report
WRBY Warby Parker	3.621 of 5 stars	$27.47 -4.6%	$29.00 +5.6%	+61.8%	$2.93B	$890.57M	1,371.34	4,036	Analyst Forecast
SLNO Soleno Therapeutics	3.568 of 5 stars	$52.95 +0.0%	$76.67 +44.8%	-29.3%	$2.76B	$190.40M	230.21	30	Negative News Analyst Forecast
LMAT LeMaitre Vascular	4.5449 of 5 stars	$98.33 -3.3%	$112.60 +14.5%	+18.9%	$2.25B	$249.60M	36.26	490
TMDX TransMedics Group	4.2149 of 5 stars	$64.08 -0.3%	$135.00 +110.7%	-43.8%	$2.22B	$605.49M	14.57	210

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGP) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyglass Pharma (SGP) Competitors

SGP vs. WRBY, SLNO, LMAT, TMDX, and AXGN

How does Spyglass Pharma compare to Warby Parker?

Summary

How does Spyglass Pharma compare to Soleno Therapeutics?

Summary

How does Spyglass Pharma compare to LeMaitre Vascular?

Summary

How does Spyglass Pharma compare to TransMedics Group?

Summary

How does Spyglass Pharma compare to AxoGen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyglass Pharma (SGP) Competitors

SGP vs. WRBY, SLNO, LMAT, TMDX, and AXGN

How does Spyglass Pharma compare to Warby Parker?

Is SGP or WRBY more profitable?

Does the media refer more to SGP or WRBY?

Which has stronger earnings & valuation, SGP or WRBY?

Do institutionals and insiders have more ownership in SGP or WRBY?

Do analysts recommend SGP or WRBY?

Summary

How does Spyglass Pharma compare to Soleno Therapeutics?

Do analysts recommend SLNO or SGP?

Is SLNO or SGP more profitable?

Does the media prefer SLNO or SGP?

Do insiders and institutionals hold more shares of SLNO or SGP?

Which has preferable valuation & earnings, SLNO or SGP?

Summary

How does Spyglass Pharma compare to LeMaitre Vascular?

Do institutionals & insiders believe in SGP or LMAT?

Does the media prefer SGP or LMAT?

Is SGP or LMAT more profitable?

Which has higher valuation and earnings, SGP or LMAT?

Do analysts recommend SGP or LMAT?

Summary

How does Spyglass Pharma compare to TransMedics Group?

Do analysts recommend TMDX or SGP?

Which has better valuation & earnings, TMDX or SGP?

Does the media favor TMDX or SGP?

Is TMDX or SGP more profitable?

Do insiders & institutionals have more ownership in TMDX or SGP?

Summary

How does Spyglass Pharma compare to AxoGen?

Does the media favor SGP or AXGN?

Do institutionals and insiders hold more shares of SGP or AXGN?

Is SGP or AXGN more profitable?

Which has stronger valuation and earnings, SGP or AXGN?

Do analysts recommend SGP or AXGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools